Replies to post #12613 on Titan Pharmaceuticals Inc (TTNP)

[KMBJN]

Added $1 to their $5 price target, so now $6, but I believe doesn't include any other drugs besides probuphine.

The major impediments in the US for probuphine sales thus far seem to be (1) Braeburn didn't have their act together, and it's possible don't have the proper incentives to market probuphine, possibly sand-bagging it and promoting their own implant instead (if it gets approved); (2) insurance companies are taking forever for pre-approval, and making it very difficult; (3) patients needed to be stabilized first, and FDA label only for maintenance treatment.

One interesting thing I didn't see Zacks or anyone else mention is that Titan is applying for approval in the EU starting at initial treatment, not just for maintenance like approved in the US:

On November 27, 2017, Titan announced that the European Medicines Agency had accepted for review its Marketing Authorization Application seeking approval of a Probuphine label that will permit the marketing of the product for use in a broad population of opioid use disorder patients, starting with initial treatment and continuing through maintenance treatment.

That combined with socialized medicine / state payors, might actually streamline things and EU could be a bigger market for probuphine vs. the US (with FDA restrictions and insurance reimbursement difficulties).

It would be great if Titan / Braeburn could petition the FDA to allow for initial treatment, especially if the new implants are allowed to do that (without even running any active comparator trials).

Who knows, maybe the insurance companies will stop making it so difficult to get reimbursed for probuphine in the US, with all the media and public awareness of the issue.

The launch is extremely disappointing, and things almost HAVE to improve - just not sure how much.

Regarding Braeburn and Titan's relationship and if Braeburn is really all-in on probuphine, doesn't Titan have some recourse there, such as (1) they are getting a cut of any other competing Braeburn OUD treatment sales - is that still true with modified license after first CRL?, or (2) Titan could cut a deal with a competitor of Braeburn, for instance for antagonist implant (or alternative pain / OUD implant). It seemed like the EU partner was prohibited from marketing any competing products for 5 years (unlike Braeburn?), and that Titan could get a cut of anything after that (IIRC).

[turks]

Hi DOC, I like Molteni,there like the complete opposite of breaburn,they might be small but they been around ovet a hundred years and they know how to get around.They really know there stuff it seems.It could possibly be the perfect match titan and molten in EU or even ROW if they play there hand right.As small as they are compare to the big companies probuphine could really expand and increase Moltenis business in addiction if like I said,they play there cards right,titan is going for the jugular for approval,initial treatment not the first stable BS in USA.I think pain is not to far off either.Hope they get there approval as soon as possible.And breaburn wakes the X up.Cash up front is decent not great or good,but what the hell could we expect,in a year aND a half+ we literally did ZERO sales thanks to breaburn,I am sure if they started getting good sales numbers we could of gotten way way more and much higher royalties.But I am find with this,got a good feeling for this partnership.Hey if opiant/titan get good results etc.molteni will have another addiction implant in there product line.